IDEAYA Biosciences (IDYA) AI Stock Analysis

• Market Cap: $1.61B
• Dividend Yield: N/A
• Average Volume (3M): 1.71M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: -54.85%
• EPS Growth: -79.25%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.82
• Shares Outstanding: 87,581,960
• 10 Day Avg. Volume: 1,408,220
• 30 Day Avg. Volume: 1,706,179
• PEG Ratio: 0.11
• Price to Book (P/B): 1.31
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $51.38
• Price Target Upside: 194.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

IDEAYA Biosciences faces key financial challenges with declining revenues and net losses, impacting its overall score. The stock's bearish technical indicators further weigh down the score, despite a positive corporate event with the appointment of a new CFO. Valuation metrics remain weak due to lack of profitability, limiting investor appeal.

Positive Factors

Clinical Trials

Management notes that enrollment continues to be robust, ahead of schedule, and 'well north' of what is needed for the accelerated approval PFS readout.

Regulatory Approval

IDYA announced IND clearance in solid tumors for DLL3-targeted Topo1 ADC, IDE849, as the company prepares to initiate a global Phase 1 clinical program.

Strategic Initiatives

IDYA announced initiation of Phase 1/2 expansion for MAT2A inhibitor IDE397 + GILD's Trodelvy in MTAP-deleted mUC, marking a key execution milestone for the doublet.

Negative Factors

Financial Concerns

IDYA has an annualized cash burn of $300 million, which may concern investors regarding long-term financial sustainability.

Investor Sentiment

Short interest represents 13.8% of the float, indicating a significant level of skepticism among some investors.

Market Perception

Investors largely overlook the opportunity due to pushbacks on market size and opportunity.

IDEAYA Biosciences Business Overview & Revenue Model

Company Description

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

How the Company Makes Money

IDEAYA Biosciences generates revenue primarily through collaborative research and licensing agreements with pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties from future product sales. Significant collaborations, such as with GlaxoSmithKline (GSK), contribute to its earnings by providing funding for research and development activities. Additionally, IDEAYA may earn revenue from government grants and other funding sources to support its clinical and preclinical programs.

IDEAYA Biosciences Financial Statement Overview

Summary

IDEAYA Biosciences faces significant financial challenges with declining revenues and consistent net losses. The company maintains a strong equity position, suggesting stability, but profitability and cash flow constraints pose risks. Strategic improvements are necessary for future growth.

Income Statement

The company has seen a significant decline in revenue over the past year, with a negative growth rate of 70%. Gross profit margin remains at 100% due to no cost of goods sold reported. However, high negative net profit, EBIT, and EBITDA margins reflect operational challenges and lack of profitability.

Balance Sheet

IDEAYA Biosciences maintains a strong equity base, with an equity ratio of 94%. The debt-to-equity ratio is low, indicating minimal leverage, but return on equity is negative due to net losses, highlighting profitability challenges.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash burn from operations. However, the company has managed substantial financing activities, improving cash reserves significantly, albeit not enough to cover the free cash flow deficit.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
7.00M	23.39M	50.93M	27.94M	19.54M
	Gross Profit
7.00M	19.38M	48.83M	26.22M	-20.16M
	EBIT
-326.98M	-134.43M	-62.50M	-50.27M	-35.34M
	EBITDA
-326.98M	-130.42M	-60.40M	-48.54M	-33.96M
	Net Income Common Stockholders
-274.48M	-112.96M	-54.81M	-47.53M	-32.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
676.32M	525.11M	373.15M	368.06M	283.58M
	Total Assets
1.12B	649.32M	387.97M	381.35M	298.27M
	Total Debt
19.17M	2.87M	3.48M	5.18M	6.72M
	Net Debt
-65.21M	-154.15M	-65.15M	-86.86M	-65.31M
	Total Liabilities
64.94M	28.23M	387.97M	381.35M	298.27M
	Stockholders Equity
1.06B	621.09M	349.45M	301.51M	198.27M
Cash Flow		Free Cash Flow
-251.44M	-117.59M	-90.62M	-58.42M	54.97M
	Operating Cash Flow
-247.58M	-115.22M	-87.17M	-55.78M	55.46M
	Investing Cash Flow
-502.56M	-158.46M	-33.40M	-69.67M	-146.24M
	Financing Cash Flow
677.55M	362.72M	97.17M	145.45M	128.75M

IDEAYA Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 17.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Negative. The current price of 17.45 is below the 20-day moving average (MA) of 18.62, below the 50-day MA of 17.89, and below the 200-day MA of 26.68, indicating a bearish trend. The MACD of 0.08 indicates Positive momentum. The RSI at 44.86 is Neutral, neither overbought nor oversold. The STOCH value of 19.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDYA.

IDEAYA Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMCR	58 Neutral	$1.48B	―	-5.78%	―	25.50%	64.63%
KYMR	55 Neutral	$2.09B	―	-32.17%	―	-25.85%	-23.89%
Sector *	52 Neutral	$5.22B	3.55	-44.39%	2.82%	15.40%	-0.09%
IDYA	49 Neutral	$1.61B	―	-31.34%	―	-54.85%	-79.25%
CGON	49 Neutral	$1.92B	―	-16.57%	―	―	―
BEAM	45 Neutral	$1.83B	―	-38.04%	―	-82.38%	-164.76%
ETNB	42 Neutral	$1.18B	―	-69.30%	―	―	-68.13%

IDEAYA Biosciences Corporate Events

IDEAYA Biosciences Announces Board Restructuring Plans

On March 28, 2025, Susan L. Kelley, M.D. notified IDEAYA Biosciences of her decision not to seek re-election to the Board of Directors at the 2025 annual meeting of stockholders. Dr. Kelley will resign from the Board at the end of her current term but will transition to an advisory role as Chair of the new Clinical Advisory Board. The company plans to reduce the Board size to seven directors after the meeting, and Dr. Kelley’s decision is not due to any disagreement with the company’s operations or policies.